Skip to main content
Pharming Group N.V. logo

Pharming Group N.V. — Investor Relations & Filings

Ticker · PHARM ISIN · NL0010391025 LEI · 724500DCJ9MPG74JEH91 AS Manufacturing
Open in API
Filings indexed 800 across all filing types
Latest filing 2012-01-24 Regulatory Filings
Country NL Netherlands
Listing AS PHARM

About Pharming Group N.V.

https://www.pharming.com/

Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company develops and commercializes an innovative portfolio of medicines to serve patients with unmet medical needs. Its portfolio includes protein replacement therapies, precision medicines, small molecules, and biologics.

Recent filings

Filing Released Lang Actions
New data published on Ruconest's effect on blood clotting parameters
Regulatory Filings Classification · 96% confidence The document is a press release dated January 24, 2012, announcing new data published in a peer-reviewed journal ('Biodrugs') regarding the safety profile of their drug RUCONEST in treating HAE attacks. It details study findings, includes commentary from the CMO, and provides background information on the drug and the company. This format—a news announcement summarizing recent developments, data releases, or corporate updates that are not formal regulatory filings like 10-K or IR—is characteristic of an Earnings Release (ER) or a general corporate announcement. Since it is announcing specific scientific/clinical data rather than quarterly financial results, and it is not a transcript (CT), investor presentation (IP), or a formal regulatory filing, it fits best as an Earnings Release (ER) if we consider scientific updates as part of the regular reporting cycle, or potentially a Regulatory Filing (RNS) if it's considered a general market-moving announcement. Given the structure and focus on new data/study results, it strongly resembles an Earnings Release (ER) which often includes operational and clinical highlights alongside financial context, or a general press release. Since 'ER' is defined as 'Initial announcement of quarterly/periodical financial results (key highlights only)', and this is a clinical data announcement, the most appropriate general category for a non-standard, market-moving announcement that isn't a specific report type is 'Regulatory Filings' (RNS) as a fallback, or if we interpret 'periodical' broadly to include significant clinical updates, ER. However, looking closely at the definitions, this is a press release announcing external publication of study results. This type of announcement is often categorized under RNS (Regulatory Filings) when it doesn't fit the specific financial report types (10-K, IR, ER). It is not a transcript, presentation, or a notice of a dividend/share change. I will classify it as RNS as it is a general regulatory/market announcement not covered by more specific codes.
2012-01-24 English
Pharming redeems part of convertible bond
Capital/Financing Update Classification · 98% confidence The document is a press release dated January 6, 2012, announcing that Pharming Group NV has redeemed part of its convertible bond and issued shares to bondholders. It discusses financing activities, capital structure changes (issuance of shares related to debt redemption), and future cash runway based on clinical milestones. This content directly relates to updates on company fundraising, financing activities, or capital structure changes, which aligns perfectly with the definition for 'Capital/Financing Update' (CAP). It is not a full annual report (10-K), an earnings release (ER), or a general regulatory filing (RNS), as it details a specific corporate finance action.
2012-01-06 English
PHARMING ANNOUNCES €8.4 MILLION CONVERTIBLE BOND FINANCING
Capital/Financing Update Classification · 98% confidence The document is titled "PHARMING ANNOUNCES €8.4 MILLION CONVERTIBLE BOND FINANCING" and details the terms of a private convertible bond, including proceeds, conversion price, coupon, and the issuance of warrants. It explicitly mentions strengthening the balance sheet and seeking shareholder approval for an increase in authorized share capital at an upcoming Extraordinary General Meeting (EGM). The core subject is a significant financing/fundraising activity. This aligns directly with the definition for Capital/Financing Update (CAP). Although it mentions an EGM, the primary focus is the financing transaction itself, not the voting results (DVA) or the EGM presentation materials (AGM-R).
2011-12-23 English
PHARMING ANNOUNCES €8.4 MILLION CONVERTIBLE BOND FINANCING
Regulatory Filings Classification · 85% confidence The document text provided is not the content of a financial filing but rather an error message indicating that the processing system failed to extract text from a .doc file because the necessary conversion tools (doc2txt, antiword) were unavailable or failed. Since there is no actual content to analyze for keywords, regulatory headers, or reporting periods, this must be classified as a miscellaneous or unprocessable filing. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback category for an unclassifiable or failed document extraction, although it technically represents a system failure rather than a standard filing type.
2011-12-23 English
PHARMING ANNOUNCES AGREEMENT WITH RENOVA LIFE TARGETING FACTOR VIII FOR THE TREATMENT OF HAEMOPHILIA A
Regulatory Filings Classification · 96% confidence The document is a press release announcing a specific business development: an agreement between Pharming and Renova Life regarding the development of Factor VIII for Haemophilia A treatment. It contains highlights, strategic context, and contact information, typical of an initial announcement rather than a comprehensive periodic report (like 10-K or IR) or a transcript. Since it is an announcement of a significant business event (a partnership/development agreement) that doesn't fit the specific categories like M&A (TAR) or Financing (CAP), it most closely aligns with a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were structured as slides. Given the format is a standard press release announcing a strategic move, RNS (Regulatory News Service/General Regulatory Announcement) is the most appropriate fallback category for significant, non-periodic corporate news that isn't explicitly covered elsewhere. The length (5067 chars) is substantial enough that it's not just a brief 'Report Publication Announcement' (RPA).
2011-12-16 English
PHARMING ANNOUNCES AGREEMENT WITH RENOVA LIFE TARGETING FACTOR VIII FOR THE TREATMENT OF HAEMOPHILIA A
Regulatory Filings Classification · 95% confidence The document is titled 'SNTS - Press Release re C.E. Unterberg Investor Conference' and contains a detailed announcement about a service agreement between Pharming Group NV and Renova Life, Inc. regarding the development of Factor VIII for Haemophilia A treatment. This is a specific corporate announcement detailing a business development, partnership, and market potential. It is not a full annual report (10-K), a quarterly report (IR), an earnings release (ER) focusing only on numbers, or a transcript (CT). It is a press release announcing a significant business agreement, which often falls under general regulatory announcements or investor relations material. Given the options, it is a specific corporate update that doesn't fit the highly specialized categories like DIV, DIRS, or DEF 14A. Since it is a press release announcing a strategic agreement, it is best classified as a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if it were a slide deck, but as a press release, RNS is the most appropriate fallback for significant, non-standard announcements, or it could be considered a type of Capital/Financing Update (CAP) if the agreement involved immediate funding, but here it is primarily a development/partnership announcement. Given the context of corporate filings, press releases announcing strategic partnerships are often categorized under RNS (Regulatory News Service/General Regulatory Filings) when a more specific category like M&A (TAR) does not apply. I will classify it as RNS as it is a general corporate announcement/press release.
2011-12-16 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.